Defendant
1 case as defendant.
EUSA Pharma (USA), Inc. was the U.S. arm of EUSA Pharma, a transatlantic specialty pharmaceutical company founded in 2006 by Bryan Morton, with U.S. operations in Doylestown/Langhorne, Pennsylvania and European offices in Oxford, UK. It was privately held, backed by investors including Essex Woodlands, 3i, Advent Venture Partners, Goldman Sachs, SV Life Sciences, TVM Capital, NeoMed and NovaQuest, and had raised over $275 million. Press at the time of its 2012 sale reported roughly 180 employees. In April 2012, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) acquired EUSA Pharma for about $650 million cash plus a $50 million sales milestone (reported at ~$700 million total). The U.S. entity was later renamed Jazz Pharmaceuticals (EUSA Pharma USA) Inc. and voluntarily dissolved (North Dakota filings show the entity inactive by 2013). The EUSA Pharma name was revived in March 2015 as EUSA Pharma (UK) Ltd (Hemel Hempstead, UK), which Recordati acquired in March 2022 for €707 million.
The original business in-licensed, developed and marketed late-stage specialty hospital products, including Erwinaze/Erwinase and Kidrolase (asparaginase for acute lymphoblastic leukemia), Caphosol (calcium phosphate rinse for oral mucositis), Collatamp (gentamicin-impregnated collagen surgical implant), ProstaScint (prostate cancer imaging), Quadramet (bone pain), Fomepizole, Xenazine (French rights) and Custodiol (organ preservation). The later UK business sold Qarziba (anti-GD2 antibody for neuroblastoma), Sylvant (anti-IL-6 for iMCD), Fotivda (VEGF receptor TKI for renal cell carcinoma) and Caphosol.
Litigation posture: an operating company on the defense side only — 1 tracked case, 0 as plaintiff. That profile is consistent with a branded pharmaceutical company defending product patents against generic challengers, not a non-practicing entity.
Tracked case: Par Pharmaceutical v. EUSA Pharma (USA), Inc., filed at the USPTO Patent Trial and Appeal Board on 9 July 2014. Par Pharmaceutical is a generic drugmaker. The filing date coincides with a wave of PTAB covered-business-method and inter partes review petitions that generic filers (including Par and Amneal) brought against Jazz Pharmaceuticals' specialty-product patents in 2014–2015; however, the case list here does not specify the patent at issue, and I could not independently confirm which patent number or product this particular proceeding concerned. No district court suits are tracked for this entity.
Covered Business Method review involving US 7,668,730, filed by Par Pharmaceutical with EUSA Pharma (USA), Inc. listed as assignee. The PTAB did not institute the review on procedural grounds.